Days Inventory is also known as Days Sales of Inventory (DSI). Ocugen's Average Total Inventories for the
three
months ended in Dec. 2024 was $0.00 Mil. Ocugen's Cost of Goods Sold for the
three
months ended in Dec. 2024 was $0.00 Mil.
The historical rank and industry rank for Ocugen's Days Inventory or its related term are showing as below:
OCGN's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 178.8 * Ranked among companies with meaningful Days Inventory only.
Ocugen's Days Inventory
stayed the same
from Dec. 2023 (0.00) to Dec. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocugen's Inventory-to-Revenue for the
three
months ended in Dec. 2024 was 0.00.
Ocugen Days Inventory Historical Data
The historical data trend for Ocugen's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ocugen's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocugen's Days Inventory Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocugen's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ocugen's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen (NAS:OCGN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ocugen's Inventory Turnover for the
three
months ended in Dec. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocugen's Inventory to Revenue for the
three
months ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ocugen Days Inventory Related Terms
Thank you for viewing the detailed overview of Ocugen's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCGN has been successfully added to your 